Enviado por Gonzonet a través de Google Reader:
vía Discover Magazine | rsslist el 5/01/12
A vaccine conferring immunity to only half the people receiving it is not generally considered a success, but malaria is a special case. The mosquito-borne disease caused by the Plasmodium parasite kills more than 700,000 people every year, the vast majority of them African children, and no vaccine has ever shown efficacy in trials. So in October, when drug maker GlaxoSmithKline announced that its new malaria vaccine cut African youngsters' infection rates by about half in a large trial, global health officials rejoiced.
...Cosas que puedes hacer desde aquí:
- Subscribirte a Discover Magazine | rsslist con Google Reader
- Empezar a utilizar Google Reader para mantenerte al día fácilmente de todos tus sitios favoritos
No hay comentarios:
Publicar un comentario